📊 BCYC Key Takeaways
Is Bicycle Therapeutics PLC (BCYC) a Good Investment?
BCYC demonstrates exceptional financial health with $559.5M cash, minimal debt, and 8+ year runway to fund development. However, pre-revenue status with negligible commercialization ($887K revenue), significant cash burn (-$66.6M FCF), and unknown pipeline viability create substantial execution risk requiring visibility into drug development progress.
Bicycle Therapeutics shows strong top-line growth and an exceptionally strong balance sheet, with $628.11M in cash, very low leverage, and ample liquidity to fund operations. However, the business remains deeply unprofitable, with operating and free cash flow losses far exceeding revenue, which suggests current growth is not yet translating into durable operating quality. Fundamentally, this is a well-capitalized but high-burn biotech story where balance-sheet strength offsets weak profitability.
Bicycle Therapeutics PLC Key Strengths (BCYC)
- Fortress balance sheet with $559.5M cash and 12.66x current ratio enabling extended development runway
- Conservative capital structure with 0.06x leverage and only $30.9M debt providing financial flexibility
- Revenue growing 105.8% YoY demonstrating early-stage commercialization traction from minimal base
- Very strong liquidity, with current and quick ratios of 11.98x and $628.11M in cash
- Low financial leverage, with debt/equity of just 0.05x and modest long-term debt
- Revenue grew 105.8% YoY, indicating meaningful business or partnership momentum
BCYC Stock Risks: Bicycle Therapeutics PLC Investment Risks
- Severe ongoing losses with -$65.5M operating income and -$66.6M free cash flow indicating unsustainable current burn rate
- Negligible revenue base of $887K reflects pre-commercialization stage with unproven market demand
- Clinical-stage biotech dependency on successful drug development and FDA approval with no pipeline visibility
- Operating margin of -340.4% and net margin of -301.7% show the business model is still far from self-sustaining
- Free cash flow of -$252.03M indicates heavy ongoing cash burn despite revenue growth
- Revenue quality may be uneven if growth is driven by milestone or collaboration payments rather than recurring commercial sales
Key Metrics to Watch
- Operating cash flow trend and absolute burn rate trajectory
- Revenue growth acceleration beyond immaterial base and product launch progress
- Cash runway depletion relative to clinical trial completion and regulatory milestones
- Quarterly operating cash burn relative to cash reserves
- Revenue mix and consistency, especially recurring product or collaboration revenue versus one-time items
Bicycle Therapeutics PLC (BCYC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.66x current ratio provides a solid financial cushion.
BCYC Profit Margin, ROE & Profitability Analysis
BCYC vs Healthcare Sector: How Bicycle Therapeutics PLC Compares
How Bicycle Therapeutics PLC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bicycle Therapeutics PLC Stock Overvalued? BCYC Valuation Analysis 2026
Based on fundamental analysis, Bicycle Therapeutics PLC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bicycle Therapeutics PLC Balance Sheet: BCYC Debt, Cash & Liquidity
BCYC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bicycle Therapeutics PLC's revenue has grown significantly by 426% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.08 indicates the company is currently unprofitable.
BCYC Revenue Growth, EPS Growth & YoY Performance
BCYC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $887.0K | -$60.8M | $-0.87 |
| Q3 2025 | $2.7M | -$26.6M | $-0.74 |
| Q2 2025 | $2.9M | -$26.6M | $-0.77 |
| Q1 2025 | $10.0M | -$26.6M | $-0.62 |
| Q3 2024 | $2.7M | -$26.6M | $-0.74 |
| Q2 2024 | $9.4M | -$26.6M | $-0.77 |
| Q1 2024 | $4.9M | -$26.6M | $-0.62 |
| Q3 2023 | $3.0M | -$26.8M | $-0.96 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bicycle Therapeutics PLC Dividends, Buybacks & Capital Allocation
BCYC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bicycle Therapeutics PLC (CIK: 0001761612)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCYC
What is the AI rating for BCYC?
Bicycle Therapeutics PLC (BCYC) has a Combined AI Grade of B from Claude (B) and ChatGPT (B) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCYC's key strengths?
Claude: Fortress balance sheet with $559.5M cash and 12.66x current ratio enabling extended development runway. Conservative capital structure with 0.06x leverage and only $30.9M debt providing financial flexibility. ChatGPT: Very strong liquidity, with current and quick ratios of 11.98x and $628.11M in cash. Low financial leverage, with debt/equity of just 0.05x and modest long-term debt.
What are the risks of investing in BCYC?
Claude: Severe ongoing losses with -$65.5M operating income and -$66.6M free cash flow indicating unsustainable current burn rate. Negligible revenue base of $887K reflects pre-commercialization stage with unproven market demand. ChatGPT: Operating margin of -340.4% and net margin of -301.7% show the business model is still far from self-sustaining. Free cash flow of -$252.03M indicates heavy ongoing cash burn despite revenue growth.
What is BCYC's revenue and growth?
Bicycle Therapeutics PLC reported revenue of $887.0K.
Does BCYC pay dividends?
Bicycle Therapeutics PLC does not currently pay dividends.
Where can I find BCYC SEC filings?
Official SEC filings for Bicycle Therapeutics PLC (CIK: 0001761612) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCYC's EPS?
Bicycle Therapeutics PLC has a diluted EPS of $-0.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BCYC's fundamental grade?
Based on our AI fundamental analysis in June 2026, Bicycle Therapeutics PLC has a B grade with 67% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BCYC stock overvalued or undervalued?
Valuation metrics for BCYC: ROE of -11.0% (sector avg: 15%), net margin of -6,857.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BCYC's AI grade for 2026?
Our dual AI analysis gives Bicycle Therapeutics PLC a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BCYC's free cash flow?
Bicycle Therapeutics PLC's operating cash flow is $-65.9M, with capital expenditures of $713.0K. FCF margin is -7,512.7%.
How does BCYC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6,857.4% (avg: 12%), ROE -11.0% (avg: 15%), current ratio 12.66 (avg: 2).